Skip to main content
. 2015 Sep 10;29(14):1855–1862. doi: 10.1097/QAD.0000000000000767

Fig. 5.

Cost-effectiveness analysis.

Fig. 5

Incremental costs and QALYs over 15 years for MSM in the United Kingdom by potential changes in testing rate and ART initiation criteria (a) with current ART drug prices (b) with a linear decline in drug prices from a current price in 2015 of 30% below the full list price to 80% below the current full list price, reflecting the potential reduction due to price discounts and use of generic drugs. ART, antiretroviral therapy; QALY, quality-adjusted life-years.